trending Market Intelligence /marketintelligence/en/news-insights/trending/5an6cgbtqawonu6vthtluw2 content esgSubNav
In This List

Spero Therapeutics director resigns; replacement named

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Spero Therapeutics director resigns; replacement named

Spero Therapeutics Inc. said Vikas Goyal will step down from the company's board.

He will be replaced by David Southwell, who served as president, CEO and director of Inotek Pharmaceuticals from July 2014 until its merger with Rocket Pharmaceuticals Ltd. in January 2018.

Southwell currently serves on the board of PTC Therapeutics Inc. and Rocket Pharmaceuticals.

Cambridge, Mass.-based Spero Therapeutics is developing treatments for multidrug-resistant bacterial infections.